Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$15.2 - $35.51 $2.16 Million - $5.04 Million
-141,997 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$21.78 - $40.45 $1.68 Million - $3.12 Million
-77,200 Reduced 35.22%
141,997 $4.73 Million
Q2 2021

Aug 16, 2021

SELL
$32.5 - $48.96 $1.23 Million - $1.85 Million
-37,700 Reduced 14.68%
219,197 $8.5 Million
Q3 2020

Nov 16, 2020

SELL
$18.49 - $27.24 $8 Million - $11.8 Million
-432,924 Reduced 62.76%
256,897 $6.88 Million
Q2 2020

Aug 14, 2020

SELL
$8.9 - $21.84 $1.41 Million - $3.46 Million
-158,400 Reduced 18.67%
689,821 $13.4 Million
Q1 2020

May 15, 2020

SELL
$7.14 - $15.99 $7.56 Million - $16.9 Million
-1,059,271 Reduced 55.53%
848,221 $8.35 Million
Q4 2019

Feb 14, 2020

SELL
$5.1 - $11.2 $2.18 Million - $4.78 Million
-426,704 Reduced 18.28%
1,907,492 $21.2 Million
Q3 2019

Nov 14, 2019

SELL
$5.38 - $8.99 $5.81 Million - $9.71 Million
-1,080,472 Reduced 31.64%
2,334,196 $13.1 Million
Q2 2019

Aug 14, 2019

SELL
$6.27 - $8.65 $3.69 Million - $5.09 Million
-588,813 Reduced 14.71%
3,414,668 $29.5 Million
Q1 2019

May 15, 2019

BUY
$4.02 - $8.04 $852,038 - $1.7 Million
211,950 Added 5.59%
4,003,481 $32.2 Million
Q4 2018

Feb 14, 2019

BUY
$3.44 - $5.76 $5.51 Million - $9.22 Million
1,601,446 Added 73.12%
3,791,531 $15.5 Million
Q2 2018

Aug 14, 2018

SELL
$12.5 - $15.0 $2.3 Million - $2.76 Million
-183,835 Reduced 7.74%
2,190,085 $28.8 Million
Q1 2018

May 15, 2018

SELL
$8.7 - $16.8 $17.6 Million - $33.9 Million
-2,017,714 Reduced 45.94%
2,373,920 $33.7 Million
Q4 2017

Feb 14, 2018

SELL
$7.35 - $12.3 $6.64 Million - $11.1 Million
-903,410 Reduced 17.06%
4,391,634 $36 Million
Q3 2017

Nov 14, 2017

BUY
$10.0 - $12.7 $53 Million - $67.2 Million
5,295,044
5,295,044 $62.7 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Bridger Management, LLC Portfolio

Follow Bridger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridger Management, LLC with notifications on news.